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Abstract 
Background: To control and eventually eliminate vivax malaria, radical treatment with primaquine (PQ) is essential 
after completion of blood-stage treatment. Although in many malaria-endemic countries, village health volunteers 
(VHVs) are engaged in diagnostic treatment of malaria in remote communities, they principally provide blood-stage 
treatment. In such a situation, access to PQ following blood-stage treatment can be a barrier to complete treatment. 
However, studies on access to PQ treatment have been scarce and limited in health facility-based settings. This study 
aimed to identify factors associated with access to PQ treatment in rural Papua New Guinea (PNG) from the commu-
nity case management perspective.
Methods: A community-based, cross-sectional survey was conducted to collect sociodemographic information 
on children under 15 years of age, their households, and their caretakers in East Sepik Province, PNG. Data collection 
lasted from February to March, 2015. Information on the diagnoses of potential non-falciparum malaria and pre-
scription of PQ in preceding year (January to December 2014) were obtained from child health-record books. Then, 
multilevel logistic regression model was used to determine the factors associated with formal health facility visits for 
PQ treatment among children with potential non-falciparum malaria.
Results: Of 420 episodes diagnosed as potential non-falciparum malaria, 46 (11%) were immediately given PQ. The 
rest were instructed to visit formal health facilities (HFs) for PQ, and the patients obtained PQ during the second visit 
to HFs was 44%. Consequently, the overall proportion of PQ prescription was 50%. Logistic regression analysis sug-
gested that among the patients who were instructed to visit HFs for PQ treatment, the initial visit to VHV and higher 
transportation costs to HF were inversely associated with PQ prescription during the second visit to an HF.
Conclusions: Few children received PQ treatment during the second visit to HFs following diagnosis of potential 
non-falciparum malaria. These findings suggest a need to establish a policy to reduce structural and economic barri-
ers and improve rural inhabitant access to PQ treatment.
Keywords: Antimalarials, Therapeutic uses, Child, Vivax malaria, Continuity of patient care, Health service accessibility, 
Patient compliance, Patient acceptance of health care, Appointments and schedules
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Background
With the global effort to control malaria, the relative 
proportion of Plasmodium vivax tends to increase in 
regions where P.  vivax and Plasmodium falciparum are 
co-endemic [1]. In countries outside Africa, vivax malaria 
accounts for 36% of total malaria cases [2]. Unlike P. fal-
ciparum, P.  vivax can remain dormant in the liver as 
hypnozoites, reemerging to cause recurrent symptoms 
and new transmissions, which comprises a major obsta-
cle to control this disease. Primaquine (PQ) is the most 
standard and approved efficacious drug used against 
hypnozoites.
In Asia–Pacific countries, P. vivax is dominant and the 
region accounts for over 80% of P. vivax cases other than 
Africa [3]. In 2009, the Asia–Pacific Elimination Network 
(APMEN) was established especially focusing on con-
trolling P. vivax with 18 affiliate countries [4]. Although, 
in all member states, PQ has been introduced as a com-
ponent of the standard treatment of vivax malaria [2], 
information on the effectiveness of PQ treatment in 
routine clinical settings is sparse. Previous studies have 
focused mainly on adherence to 14 days’ administration 
of PQ with varied adherence rate from 24 to 98% [5–8]. 
In addition, these studies showed that males, children, 
side effects, oral instruction for treatment, and improve-
ment or worsening of symptoms tended to be related to 
nonadherence.
In many malaria-endemic countries, village health vol-
unteers (VHVs) are often the first point of contact with 
medical services. Among APMEN countries, 11 coun-
tries have deployed VHVs for malaria diagnosis and 
treatment in remote communities [9–19]. However, the 
VHVs have generally engaged in blood-stage treatment of 
vivax malaria, and have not been allowed to prescribe PQ 
because of safety concerns about severe acute haemolytic 
anaemia in glucose-6-phosphate dehydrogenase (G6PD)-
deficient patients. Although the possibility of PQ deliv-
ery by VHVs was discussed in the international meeting 
for vivax elimination in 2016, the current guideline of the 
World Health Organization (WHO) does not endorse 
this option [4].
In Papua New Guinea (PNG) one of the APMEN coun-
tries, the different Plasmodium species co-exist, and P. 
vivax is a major contributor to high morbidity rates for 
malaria, especially in young children [20, 21]. The inci-
dence of P. vivax malaria is seasonal and reaches a peak 
in the early rainy season, from October to November 
[21]. A new national malaria-treatment protocol was 
officially announced in 2009, and parasite-based diagno-
ses using microscopy or rapid diagnostic testing became 
required instead of symptom-based diagnoses. In our 
previous study in PNG, of the febrile children who sought 
treatment outside the home, 60% had first consulted 
VHVs [15]. However, PQ has been provided only in for-
mal health facilities where health providers can clinically 
assess a patient for potential PQ-induced haemolysis, and 
children diagnosed with vivax malaria are instructed to 
visit HFs to obtain PQ after blood-stage treatment with 
artemether–lumefantrine (AL) in a community level.
In such a situation, access to PQ treatment during the 
second visit to an HF following blood-stage treatment 
can be a barrier to complete the treatment. However, 
previous studies on access to PQ treatment have been 
scarce, and limited in health facility-based settings [22–
24]. Therefore, access to PQ treatment was investigated, 
including referrals from VHVs to HFs in an actual low-
resource setting, as well as associated factors from the 
community case management perspective, to propose 
policy recommendations for controlling vivax malaria in 
the Asia and Pacific region.
Methods
Study site
The study was conducted in the Boiken Dagua Rural 
Local Level Government area of Wewak district, located 
on the northern coast of East Sepik Province, PNG. In 
East Sepik Province, P. vivax is the second-most prevalent 
parasite after P.  falciparum; the overall mean prevalence 
of P.  vivax was 35.7% [20]. In PNG, non-governmental 
organizations have promoted the deployment of VHVs 
since the early 2000s [25–27]. There were 23 villages in 
the study area, and one VHV was deployed in each vil-
lage. Details of VHV framework have been previously 
described [28]. The term “health facility” (HF) was used 
to define a formal facility operated by health profession-
als approved to prescribe PQ. At the time of this study, 
five HFs (one health centre and four aid posts) were oper-
ated in the study area.
High-grade P. vivax chloroquine (CQ) resistance was 
reported in PNG in the 1990s [29, 30], therefore, com-
binations of CQ or amodiaquine with sulfadoxine-
pyrimethamine (SP) for P. vivax were introduced in 2002. 
Because of the subsequent rapid increase in SP resist-
ance, a drug efficacy trial comparing AL, dihydroarte-
misinin–piperaquine (DHA–PPQ), and CQ + SP was 
conducted between 2005 and 2007 [31]. This showed that 
the AL regimen was the most efficacious against P. vivax, 
followed by the DHA–PPQ, and CQ + SP regimens. For 
these reasons, AL became a first-line treatment for vivax 
malaria in the new national malaria-treatment protocol 
in 2009 [32].
Since then, PQ, which the former guideline rec-
ommended only for vivax malaria patients in low 
malaria-endemic regions [33], has become a standard 
treatment for all patients diagnosed with uncomplicated 
vivax and/or ovale malaria after completing 3  days of 
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treatment with AL. If a patient’s G6PD deficiency status 
is unknown, health providers should advise the patient to 
stop PQ and return to the health facility if they pass dark-
coloured urine, or they should clinically assess the patient 
for a minimum of 1 h following the administration of PQ 
[34]. Following WHO recommendations [35], a dose of 
0.25 mg/kg daily for 14 days was adopted for radical cure 
of P. vivax in the PNG guideline. In the study area, a rapid 
diagnostic test (RDT; CareStart™ Malaria HRP2/pLDH 
(pf/PAN) Combo, Access Bio Inc., USA) was widely used 
instead of microscopic diagnosis, and PQ treatment was 
recommended for patients diagnosed with “potential 
non-falciparum malaria”, i.e., “a non-P. falciparum,” “P. 
falciparum, or P. falciparum with another species.”
Study population and data collection
A community-based, cross-sectional survey using a 
structured questionnaire was conducted during February 
and March 2015. The study population included children 
aged 0 to 14 years living in coastal lowlands of the catch-
ment area of Dagua Health Centre. The area consisted of 
23 villages with 1056 households and 2767 children. A 
structured questionnaire was used for collecting infor-
mation, and it was written in English (one of the official 
languages of PNG). Coauthors (TT, MS and TF) were 
able to communicate in the local language (Tok Pisin: 
lingua franca and another official language of PNG) and 
they instructed field assistants on the intended meaning 
of each question and how to administer the questionnaire 
in Tok Pisin. Trained field assistants interviewed caregiv-
ers of the target children to collect sociodemographic 
information. Medical records of malaria diagnosis results 
and subsequent treatment regimens for study partici-
pants during the preceding year were also collected (Jan-
uary to December 2014). Individual outpatient records 
were not kept in the study area’s HFs. Instead, VHVs, as 
well as medical personnel of HFs are ordered to fill out 
medical information in a child health-record book, which 
each patient retained at home and was expected to bring 
to each VHV/HF visit. For that reason, trained field assis-
tants visited each household and collected child health-
record books; the relevant pages from these books were 
photocopied and then returned to the caregivers. Then, 
the necessary information for the study was encoded and 
was single-entered into a database table.
Data analysis
Following local guidelines, episodes with potential non-
falciparum malaria were included for the logistic regres-
sion analysis. The dependent variable was “access to PQ”, 
defined as the PQ prescription during the second visit 
to HFs following diagnosis of potential non-falciparum 
malaria. The child’s gender, child’s age, caregiver’s age, 
caregiver’s education level, caregiver’s marital status, 
total number of residents in the household, durable 
assets in the household, place of initial visit (an HF or a 
VHV), and transportation costs were identified as inde-
pendent variables.
In this study, the caregiver’s education level was speci-
fied as the total years of schooling. Household size was 
defined as the total number of residents in the household. 
On the basis of 13 dummy asset variables (pig, chicken, 
clock, mobile phone, radio, generator, chain saw, solar 
panel, car, bicycle, computer, television, and refrigerator), 
an asset index, as a predictor of household economic sta-
tus, was calculated using principal component analysis 
(PCA) [36, 37]. The asset index was scored on the basis 
of the first principal component. Thereafter, these scores 
were divided equally into three categories: upper, middle 
and lower.
Transportation cost was defined as the cost of return 
fare of transport vehicle from the nearest roadside to 
HFs. There was no charge to receive PQ, including 
related consultation and treatment costs, at HFs, so the 
direct cost to patients and their caregivers equaled only 
transportation cost.
All data were entered into a Microsoft Access 2013 
database and were then analysed using Stata SE14 (Stata 
Corp., College Station, TX, USA). After the characteris-
tics of the children, caregivers, and households surveyed 
were entered, a three-level multilevel random intercept 
logistic regression model was used to identify the associ-
ation between PQ prescription during the second visit to 
an HF and those characteristics. In the analysis, potential 
non-falciparum malaria episodes (level 1) were nested 
in an individual (level 2) and individuals were nested in 
a village (level 3). Wilcoxon rank-sum tests were used 
to compare medians of continuous variables, and Chi-
square tests were applied to compare proportions of 
categorical variables between the groups. The level of sta-
tistical significance was set at p < 0.05.
Results
Potential non‑falciparum malaria episodes for multilevel 
logistic regression analysis
This study population included 2767 children under 
age 15 registered in the household questionnaire sur-
vey. Of these, 30% (835/2767) were excluded because 
of uncollected child health-record books: children had 
no book (16% [437/2767]); children had moved out of 
the community at the time of record-book collection 
(11% [312/2767]); caregivers declined to provide a child 
health-record book (3% [86/2767]). Descriptive statistics 
of the characteristics of children in the excluded group 
(n = 835) were compared with those in the remaining 
group (n = 1932). There were significant differences in 
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the age of the patients, the age of the caregivers, the mar-
ital status of caregivers, household size, and wealth status 
between the two groups (Additional file 1: Table S1).
Among the remaining 1932 children, 684 were exam-
ined for malaria infection using RDT at least once during 
the study period. A total of 1059 RDTs were performed. 
Of these, 639 (60%) were excluded (77 had a P.  falcipa-
rum single infection, 437 had negative RDT results, 125 
had improper or unrecorded RDT or PQ prescription 
results). Among the remaining 420 episodes diagnosed 
as potential non-falciparum malaria, 50% (210/420) 
were prescribed PQ including 46 episodes (11%) which 
were directly prescribed PQ at their initial medical care. 
Finally, 374 potential non-falciparum malaria episodes 
were selected for the logistic regression analysis (Fig. 1).
PQ prescription during the second visit to HF
Of 374 potential non-falciparum malaria episodes in 
which children were directed to revisit HFs for PQ treat-
ment, 164/374 (44%) were prescribed PQ during the sec-
ond visit to HFs (Fig.  1). The median between the first 
visit (when blood-stage treatment with AL commenced) 
and the second visit to HFs (when patients obtained PQ 
treatment) was 4 days (interquartile range [IQR] 3, 6) in 
164 episodes. Among 210 episodes with no PQ prescrip-
tion, four visited HFs within 14  days after diagnosis of 
potential non-falciparum malaria. Some children had 
multiple potential non-falciparum malaria episodes dur-
ing the study period. On average, 1.2 potential non-fal-
ciparum malaria episodes per child (374 episodes in 309 
children) were seen, with a maximum of three episodes 
in one child.
Characteristics of children, their caregivers, and their 
households
Descriptive statistics of the characteristics of children 
included in the analysis are shown in Table 1. Of the 309 
children who received at least one diagnosis of potential 
non-falciparum malaria, 54% were boys, and the median 
age was 7 years (IQR 4, 10). Most of caregivers were mar-
ried (92%), and the median caregiver age was 34  years 
(IQR 28, 42). The median number of years of education 
was 6 (IQR 6, 8). The median household size was 6 (IQR 
5, 7), with a maximum of 17 people in one household. 
The median transportation cost to HFs was 0 kina ([IQR 
0, 4], Kina 1 = USD 0.37 in 2015).
Determinants of PQ prescription during second visit to HF
Using a three-level multilevel random intercept logistic 
regression model, place of initial visit and transporta-
tion cost to HFs were factors significantly associated with 
obtaining a PQ among children with potential non-falci-
parum malaria. Patients who visited VHVs at initial visit 
420 Potential non-falciparum 
malaria episodes 
46 Prescribed PQ directly
164 Obtained PQ during 
the second visit to HFs
210 Not obtained PQ
374 Ordered to visit HFs for PQ
Access to PQ
=164/374 (44%)
Abbreviations: HFs, health facilities; PQ, primaquine
Fig. 1 Access to PQ treatment. Access to PQ treatment was 
calculated as the ratio between the number of patients with potential 
non-falciparum malaria who received PQ during the second visit to 
HFs and the number directed to visit HFs
Table 1 Sociodemographic characteristics of  children 
with  potential non-falciparum malaria who were directed 
to visit an HF for PQ
Shapiro–Wilk’s normality test found all continuous variables to be non-normally 
distributed
VHV village health volunteer, HF formal health facility, IQR interquartile range
a PNG Kina 1 = USD 0.37 in 2015
Variable Value
Gender of patients—n (%)
 Male 167 (54.0)
 Female 142 (46.0)
Age of patients, years—median [IQR] 7 [4–10]
Age of caregivers, years—median [IQR] 34 [28–42]
Educational level of caregivers, years—median [IQR] 6 [6–8]
Marital status of caregivers—n (%)
 Married 286 (92.6)
 Unmarried 6 (1.9)
 Divorced or separated 10 (3.2)
 Widowed 7 (2.3)
Household size—median [IQR] 6 [5–7]
 Missing—n 1
Wealth status—n (%)
 Lower 107 (36.0)
 Middle 90 (30.3)
 Upper 100 (33.7)
 Missing 12
Transportation cost to HFs,  Kinaa—median [IQR] 0 [0–4]
 Missing—n 4
Place of initial visit—n (%)
 VHV 168 (54.4)
 HF 141 (45.6)
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were less likely to be prescribed PQ during the second 
visits to HFs (OR = 1.92, 95% CI 1.00–3.69, p = 0.049), 
and higher transportation cost to HFs was associated 
with lower odds of PQ prescription (OR = 0.85, 95% CI 
0.76–0.94, p = 0.002) (Table 2).
Discussion
The study’s main findings were as follows. First, the over-
all proportion of patients with potential non-falciparum 
malaria who received PQ was 50%. Second, the propor-
tion of patients who received PQ during the second visits 
to HFs was 44%. Third, a multilevel logistic analysis sug-
gested that the initial visit to a VHV and higher trans-
portation costs were inversely associated with the PQ 
prescription during the second visit to an HF.
The 50% proportion of patients who received PQ was 
lower than that found by previous studies in the Peru-
vian Amazon (78%) [22] and in Indonesia (65%) [23]. 
However, these studies have investigated proportions 
of patients who received PQ treatment from medi-
cal records or patients’ self-reports in medical facilities 
where patients visited. Thus, cases of referral patients are 
not included, and this may have resulted in a higher pro-
portion of patients who reached PQ treatment.
The present study found children diagnosed with 
potential non-falciparum malaria in HFs were more likely 
to obtain PQ during their second HF visit than those 
diagnosed by VHVs (Table  2). These results may have 
been due to VHV’s inadequacy of specific instructions to 
patients. In PQ treatment-adherence studies in the Bra-
zilian Amazon, patients who received adequate prescrip-
tion instruction by health-care providers were more likely 
to adhere to treatment [38]. In the study area, VHVs did 
not receive refresher training after they completed ini-
tial short-term training for malaria case management. 
In addition, VHVs were not authorized to prescribe PQ, 
whereas HF health-care providers prescribe PQ as part 
of their daily work, so VHVs may not properly explain to 
the patients about the importance of the visit an HF for 
PQ. Moreover, disease severity may affect HF visits for 
PQ. Several studies showed that treatment seeking in the 
formal health sector was associated with disease severity 
[39, 40], and from that perspective, more severe patients 
may consult with HFs than VHVs and are likely to con-
tinue PQ treatment at HFs.
In the present study, higher transportation costs were 
negatively associated with PQ prescription during the 
second visit to an HF (Table  2). Transportation costs 
may substantially impact the study population and pres-
sure people to sacrifice other living expenses. Although 
no studies have evaluated the effect of transportation 
costs on access to PQ treatment, several have shown 
association between transportation cost and appropriate 
treatment-seeking behaviour in an acute phase [41, 42]. 
In addition, this aligns with results from previous stud-
ies focusing on retention rates and transportation costs 
among patients with human immunodeficiency virus 
(HIV) in rural Haiti and Uganda [43, 44].
To improve access to HFs for PQ, structural and eco-
nomic barriers may be critical elements to consider. Thus, 
four possible policy options are proposed: (1) decentral-
izing medical care by enabling VHVs to prescribe PQ, 
(2) free public transportation to HFs, (3) PQ provision 
through routine outreach activities, and (4) concurrent 
prescription of AL and PQ.
First, decentralization of PQ treatment could be a 
promising solution. In rural PNG, VHVs have been iden-
tified as a key basic health-care provider and have diag-
nosed and treated acute malaria patients. VHVs are the 
most accessible of health-care personnel for residents; 
therefore, empowering them to prescribe PQ could be an 
efficient and feasible way to improve access. For VHVs, a 
decentralized treatment of PQ would give greater respon-
sibility in treating patients with vivax malaria. Among 
residents, this practice could increase interest about and 
understanding of PQ. Additionally, VHVs that are closer 
to residents have potential to more effectively improve a 
therapeutic course via directly observed therapy, such as 
medication adherence and monitoring risk of haemolysis 
among people with G6PD deficiency. However, in terms 
of G6PD deficiency, as haemolytic risk is considered to 
Table 2 Three-level logistic regression of  factors 
associated with  PQ prescription during  the  second visit 
to HF
Transportation cost to the HF (p = 0.002) and place of initial visit (p = 0.047) 
were significantly affected PQ prescription during the second visit to an HF. The 
significance level was p < 0.05
VHV village health volunteer, HF health facility, OR odds ratio, CI confidence 
interval
Variable OR (95% CI) p‑value
Gender of patients (female = 0/male = 1) 1.23 [0.68, 2.23] 0.49
Age of patients (year) 1.05 [0.96, 1.15] 0.31
Age of caregivers (year) 1.03 [0.99, 1.06] 0.16
Educational level of caregivers (year) 1.02 [0.92, 1.14] 0.66
Marital status of caregivers (married = 1)
   Unmarried 1.08 [0.17, 6.88] 0.94
   Divorced/separated 1.78 [0.37, 8.52] 0.47
   Widowed 0.25 [0.03, 2.19] 0.21
Household size 0.92 [0.81, 1.04] 0.19
Wealth status (Lower = 1)
   Middle 0.82 [0.40, 1.68] 0.59
   Upper 0.73 [0.35, 1.52] 0.41
Transportation cost to HF (PNG Kina) 0.85 [0.77, 0.94] 0.002
Place of initial visit (VHV = 0/HF = 1) 1.94 [1.01, 3.71] 0.047
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be high in PNG [45, 46], sufficient preliminary assess-
ment of tolerability and safety of PQ administration must 
first be conducted. In cases where nonmedical workers 
intervene in PQ treatment, screening using point-of-care 
G6PD testing is recommended for the risk management 
of haemolysis in low-resource settings [47].
Second, free transportation could be a helpful incen-
tive to revisit HFs. Currently, in PNG, examinations and 
PQ treatment are free at HFs, so the only direct cost for 
patients and their families is transportation. In a study 
conducted in Tanzania, funding assistance to cover 
the transportation cost of returning to the hospital was 
associated with improved adherence to follow-up pro-
tocols among children diagnosed with tuberculosis [48]. 
Similarly in Malawi, transportation cost to a hospital was 
associated with improved long-term follow-up in antiret-
roviral treatment among adult HIV patients co-infected 
with tuberculosis [49]. However, cost-effectiveness 
assessment, including management cost, would be neces-
sary for the perspective of sustainability in PNG.
Third, the availability of routine outreach activities 
could improve PQ treatment for rural residents. In the 
study area, childcare-outreach services visit each village 
every 2  months to administer vaccinations and health 
examinations for children, providing PQ treatment as 
part of the outreach services may therefore be partly 
effective for reducing vivax transmission. PNG has a 
short-term relapsing strain in which multiple relapses are 
very common (similar to the Chesson strain; with which 
80% of relapses occur within 1  month after the treated 
primary infection) [50]. Even if PQ treatment is given 
more than 2  months after the disease onset by the out-
reach services, it is still possible to reduce the number of 
relapses and infection transmission. Furthermore, during 
routine visits to each village, health-care professionals 
can monitor the signs and symptoms of possible adverse 
reactions for patients already given PQ treatment, and 
can also mentor the VHVs and share with them relevant 
health-care information on PQ-induced adverse reac-
tions. These policies may lead to better implementa-
tion of treatment for needy children infected with vivax 
malaria.
Last, concurrent prescription of AL and PQ, which has 
been adopted in Vanuatu could increase the proportion 
of patients obtaining PQ treatment: PQ is prescribed with 
AL once and started on the same day with AL. Vanuatu’s 
national guidelines recommended the routine testing of 
G6PD deficiency before PQ administration, and require 
clinical monitoring at higher level health facilities for 
patients with an unknown G6PD status at the time they 
received PQ treatment [51]. However, concurrent pre-
scription needs some consideration. Eventual adherence, 
including 14  days oral administration, is unclear unless 
differences are compared between patients prescribed 
PQ at the initial visit and at the second visit. Moreover, 
little is known about the safety and efficacy of concurrent 
use of AL and PQ. Some partner blood schizonticides, 
including AL may affect PQ metabolism via inhibition of 
cytochrome P450-2D6 activity [1, 52]. For these reasons, 
health facilities should establish emergency responses to 
G6PD deficiency, such as blood transfusion for an acute 
haemolytic event. Furthermore, patients should be given 
instructions about the signs and symptoms of possible 
adverse reactions (such as dark-coloured urine, gastroin-
testinal symptoms and fatigue), emphasizing the neces-
sity of a return visit if the patient experiences any of those 
adverse reactions.
Apart from the possible changes in policy as mentioned 
above, current PQ administration in the study setting 
may be problematic; it was found that PQ was prescribed 
for patients with an RDT result of “falciparum malaria or 
falciparum malaria with infections of other malaria spe-
cies”, although the national guidelines recommend that 
PQ should be prescribed only when confirmed as vivax 
and/or ovale malaria [34]. Therefore, the observed PQ 
treatment may lead to overuse of PQ and any subsequent 
unnecessary adverse reactions. It is rather preferable to 
establish a referral system to ensure a definitive diagno-
sis using a microscope or P. vivax-specific bivalent RDT 
toward the elimination stage of vivax malaria. In the 
present study setting, it is feasible to make a blood film 
diagnosis for malaria at the HF and refer to the provin-
cial hospital for microscopic examination. In this situa-
tion, it is more important to strengthen a referral system 
between VHVs and HFs for elimination stage of vivax 
malaria at a community level.
The present study has some limitations. First, PQ pre-
scription during the second visits to HFs among chil-
dren with potential non-falciparum malaria was assessed 
through inspection of child health-record books. Possi-
bly, health-care providers did not always enter patients’ 
information in record books, and therefore, the propor-
tion of children completing the requisite HF visits for 
PQ could be biased. However, this study is perceived 
to be more credible than a previous study evaluating 
the proportion of PQ prescriptions through patients’ 
self-reports [23]. Second, access to PQ treatment was 
defined as obtaining PQ during a second HF visit follow-
ing diagnosis of potential non-falciparum malaria. The 
word “access” originally has three dimensions, including 
availability, affordability, and acceptability [53]. How-
ever, the present study mainly focused on the former two 
aspects, excluding acceptability—such as perception of 
malaria disease and its severity, belief in the effective-
ness of medicine, knowledge and perception of the risk of 
its adverse reactions, characteristics of health providers, 
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and physician–patient relationships—that could affect 
the second visit to HF and subsequent PQ prescription. 
Third, indirect costs (the total costs of travel, waiting, and 
consultation time) could not be included in the analysis 
because it was not possible to obtain sufficient informa-
tion to estimate these costs. The effect of costs on the 
PQ access may be overestimated. Fourth, the descriptive 
statistics of several explanatory variables showed signifi-
cant differences between the excluded and the remaining 
groups, although there was no significant difference in 
the median of the significant determinant of PQ access 
(i.e., the transportation cost to the HFs). This could have 
resulted in a selection bias on the results of the logistic 
regression analysis. Fifth, because not all communities in 
rural area of PNG have working VHV programmes, gen-
eralizing these results to the rest of the region might be 
difficult. However, this study might provide useful infor-
mation for policy planning in regions that face similar 
problems.
Despite these limitations, the present study showed 
that there is inadequate access to PQ treatment in rural 
areas of PNG. Given the continuing global effort toward 
eliminating vivax malaria, further studies exploring PQ 
treatment from the stand point of community case man-
agement is important where VHVs are often the first con-
tact point, which could contribute to establishment of 
better strategies for vivax malaria elimination in the Asia 
and Pacific region.
Conclusions
Few children obtained PQ treatment during their second 
visits to HFs following diagnosis of potential non-falci-
parum malaria in rural PNG. These findings suggest that 
inadequate referrals from VHVs to HFs, and economic 
barriers of traveling to HFs, were critical factors in the 
access to PQ treatment. Vivax malaria-control policy 
making should focus on ways to increase access to PQ, 
such as the decentralization of treatment, free transpor-
tation, enhancement of outreach activity, and concurrent 
prescription of AL and PQ.
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